Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

被引：0
作者：
Teddy Kosoglou
Walter K. Kraft
Bharath Kumar
Paul Statkevich
Fengjuan Xuan
Lei Ma
Lisa K. Jennings
James E. Schiller
Ronald B. Langdon
David L. Cutler
机构：
[1] Merck Sharp & Dohme Corp.,Department of Pharmacology and Experimental Therapeutics
[2] Thomas Jefferson University,Clinical Pharmacology, Merck Research Laboratories
[3] University of Tennessee Health Science Center,undefined
[4] Merck Sharp & Dohme Corp.,undefined
来源：
European Journal of Clinical Pharmacology | 2012年 / 68卷
关键词：
Vorapaxar; SCH 530348; PAR-1; Renal disease; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1049 / 1056
页数：7
相关论文
共 50 条
[31]   PHARMACOKINETICS OF TORASEMIDE AND ITS METABOLITES IN END-STAGE RENAL-DISEASE [J].
KRAMER, BK ;
SCHWAB, A ;
BRAUN, N ;
STRUTZ, F ;
MULLER, GA ;
RISLER, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 47 (02) :157-159
[32]   Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis [J].
Noorani, Behnam ;
Menon, Rajeev M. ;
Chen, Xin ;
Marsh, Kennan C. ;
Huang, Weize ;
Gupta, Shelly ;
Dobkowska, Edyta ;
Marbury, Thomas ;
Salem, Ahmed Hamed .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (03) :748-758
[33]   PHARMACOKINETICS OF ZIDOVUDINE IN END-STAGE RENAL-DISEASE - INFLUENCE OF HEMODIALYSIS [J].
PACHON, J ;
CISNEROS, JM ;
CASTILLO, JR ;
GARCIAPESQUERA, F ;
CANAS, E ;
VICIANA, P .
AIDS, 1992, 6 (08) :827-830
[34]   Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease [J].
Nishimura, Marin ;
Hsu, Jonathan C. .
AMERICAN JOURNAL OF CARDIOLOGY, 2018, 121 (01) :131-140
[35]   Safety and Pharmacokinetics of Subcutaneously Administered Rilonacept in Patients With Well-Controlled End-Stage Renal Disease (ESRD) [J].
Radin, Allen ;
Marbury, Thomas ;
Osgood, Greg ;
Belomestnov, Pavel .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (07) :835-841
[36]   Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions [J].
Leuppi-Taegtmeyer, Anne ;
Duthaler, Urs ;
Hammann, Felix ;
Schmid, Yasmin ;
Dickenmann, Michael ;
Amico, Patricia ;
Jehle, Andreas W. ;
Kalbermatter, Stefan ;
Lenherr, Christoph ;
Schwabedissen, Henriette E. Meyer Zu ;
Haschke, Manuel ;
Liechti, Matthias E. ;
Krahenbuhl, Stephan .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (04) :692-702
[37]   Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis [J].
Pai, Sudhakar M. ;
Chaikin, Philip ;
Berg, Jolene Kay .
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (10) :1379-1383
[38]   HBV infection in patients with end-stage renal disease [J].
Fabrizi, F ;
Bunnapradist, S ;
Martin, P .
SEMINARS IN LIVER DISEASE, 2004, 24 :63-70
[39]   Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis [J].
Patel, Kashyap ;
Rayner, Craig R. ;
Giraudon, Mylene ;
Kamal, Mohamed A. ;
Morcos, Peter N. ;
Robson, Richard ;
Kirkpatrick, Carl M. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (04) :624-635
[40]   PHARMACOKINETICS OF INTRAVENOUS VANCOMYCIN IN PATIENTS WITH END-STAGE RENAL-FAILURE [J].
TAN, CC ;
LEE, HS ;
TI, TY ;
LEE, EJC .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :29-34
12345